Use of Ovarian Tumor Markers in Prediction of Malignancy Risk in Pediatric and Adolescent Patients
Topic overview
Multi-institutional study of 309 pediatric/adolescent patients evaluated preoperative tumor marker combinations for predicting ovarian mass malignancy. β-HCG combined with AFP/CA-125/inhibin A achieved 100% negative predictive value, enabling safer identification of candidates for ovary-sparing surgery and reducing unnecessary oophorectomy for benign disease.
Key takeaways
- β-HCG was present in all best-performing tumor marker combinations for predicting ovarian malignancy in pediatric patients.
- The combination of AFP/β-HCG/CA-125/inhibin A achieved 100% negative predictive value, ensuring no malignancies were missed.
- β-HCG/inhibin A/LDH combination showed highest overall accuracy (95.1%) for malignancy risk stratification.
- Appropriate tumor marker selection can guide ovary-sparing surgery decisions and reduce unnecessary oophorectomies for benign disease.
- Multi-marker panels outperform individual tumor markers in preoperative risk assessment of pediatric ovarian masses.
Comments